Table 4.
Sputum-smear conversion in vitD3+PBA versus placebo
| Crude | Adjusteda | |||||||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Endpoint | Week | n | OR | 95% CI | P Value | OR | 95% CI | P Value |
| Smear-positive patients (mITT) | ||||||||
| Sputum-positivity | 4 | 199 | 0.45 | (0.23 to 0.87) | 0.017 | 0.49 | (0.25 to 0.94) | 0.037 |
| 8 | 199 | 1.07 | (0.43 to 2.65) | 0.879 | 1.05 | (0.42 to 2.63) | 0.904 | |
| Smear-positive patients (per-protocol) | ||||||||
| Sputum-positivity | 4 | 173 | 0.46 | (0.23 to 0.90) | 0.024 | 0.48 | (0.24 to 0.95) | 0.038 |
| 8 | 174 | 1.29 | (0.48 to 3.42) | 0.616 | 1.29 | (0.48 to 3.47) | 0.584 | |
| Smear-positive patients with elevated 25(OH)D3 levels at week 4 (per-protocol) | ||||||||
| Sputum-positivity | 4 | 170 | 0·98 | (0·97–1·00) | 0·005 | 0·99 | (0·97–1·00) | 0·008 |
OR, odds ratio; CI, confidence interval; mITT, modified intention-to-treat
a
Data are adjusted for gender, age and sputum-smear positivity at baseline.